Adenomyosis is defined as ectopic endometrial tissue within the musculature of the uterus. It is a challenging condition in that it often overlaps in symptoms and is found in conjunction with other gynecologic disorders, including endometriosis and uterine leiomyoma (fibroids). The typical clinical manifestations of adenomyosis occur in women who are 40 to 50 years of age and include abnormal uterine bleeding and dysmenorrhea (65% of patients). The exact pathogenesis is not fully defined but is thought to be the result of direct invagination of the endometrium into the myometrium. The interventionalist’s role is to offer uterine artery embolization (UAE), which provides some benefits over traditional medical and surgical therapies for adenomyosis.

**IMAGING FOR ADENOMYOSIS**

Transvaginal ultrasound (TVUS) and MRI are often utilized for the noninvasive diagnosis of adenomyosis. Just as the clinical symptomatology can overlap with other pelvic conditions, imaging also has limitations because there are no standard diagnostic criteria for adenomyosis and many uterine lesions can coexist on imaging.

Classic findings of adenomyosis on ultrasound include heterogeneous myometrial echotexture, asymmetric thickening of the wall of the myometrium, myometrial cysts, subendometrial echogenic linear striations, and poor definition of the endometrial–myometrial junction. With TVUS, the findings of adenomyosis are often observer dependent and can be difficult for the less experienced clinician. It has been suggested that use of sonohysterography allows for an important distinction between myometrial and endometrial lesions because of the added benefit of a distended endometrial cavity, leading to improved diagnostic accuracy.

The question then becomes what, if any, benefit is there to performing an MRI? Typical findings of adenomyosis on MRI include thickening of the junctional zone exceeding 12 mm and high-signal-intensity foci on T2/T1-weighted images similar to the case shown in Figure 1. Many studies have evaluated the diagnostic accuracy of TVUS and MRI techniques for adenomyosis. TVUS has a sensitivity of approximately 72% and specificity of 81% versus 77% and 89% for MRI, respectively. In addition, MRI can provide greater detail about the extent of disease and additional uterine lesions, as well as information about the less common presentation of adenomyosis, where focal disease in the form of an adenomyoma is present rather than the more typical diffuse adenomyosis findings.
TREATMENT OPTIONS

Management of symptomatic adenomyosis can include medication, hysterectomy, conservative surgery, or UAE. Conventional treatment with hysterectomy allows for definitive diagnosis and treatment; however, medications, conservative surgery, and UAE are less invasive techniques that permit preservation of the uterus and possible fertility.

Medical therapies using suppressive hormonal treatments, such as continuous use of oral contraceptive pills, high-dose progestins, selective estrogen/progesterone receptor modulators, the levonorgestrel intrauterine device, aromatase inhibitors, danazol, and gonadotropin-releasing hormone receptor agonists, can improve symptoms by temporarily inducing regression of adenomyosis. Unfortunately, many of these medical options do not provide sustained improvement and are limited by their menopausal-like side effects as well as temporarily blocking the ability to conceive.

For reproductive-age women and those with focal adenomyoma, conservative surgical approaches may be a better option. A recent systematic review of excisional and nonexcisional surgical approaches, including adenomyomectomy with or without myomectomy reduction, endomyometrial ablation or resection, electrocoagulation of adenomyoma, and myometrial excision, found that more than 75% of women experienced symptom relief with these conservative surgical treatments. However, recurrence rates varied from 9% to 32%, depending on the technique.

Although hysterectomy is the gold standard for diagnosis and treatment of adenomyosis, it is reserved for women who have completed childbearing. Vaginal, laparoscopic, and abdominal hysterectomies vary in recovery time and postoperative morbidity. Although hysterectomy is known as the definitive treatment for adenomyosis, interestingly, pelvic pain is not necessarily eliminated in patients who undergo hysterectomy. Stovall et al found that despite a histologic confirmation of uterine pathology in patients with chronic pelvic pain, nearly one-quarter of patients had continued pelvic pain after hysterectomy.

With the limitations of the aforementioned techniques, several studies have investigated the use of UAE for adenomyosis and have shown promise. Overall, there is a lack of sufficient randomized trial data to support one treatment over another, and several factors, including age, severity of symptoms, desire for future fertility, and associated comorbidities, should be considered in the evaluation.

UTERINE ARTERY EMBOLIZATION

Preprocedural Evaluation

When considering UAE for the treatment of adenomyosis, all patients at our institution have a preprocedural consultation, which allows for review of the symptomatology, a physical examination, and imaging. The first question that is answered in this setting is, “Does this imaging finding of adenomyosis explain the patient’s symptoms?” If the patient has dysfunctional uterine bleeding such as bleeding between cycles, endometrial biopsy is sometimes recommended to be performed by a gynecologist before considering embolization, based on the American College of Obstetricians and Gynecologists guidelines.

Each patient will be asked about their desire for future fertility, and a brief overview of the aforementioned alternative options will be presented when appropriate. Simplified pictures of the pelvis and catheter placement are used during description of the procedure. The outcomes of the procedure and possible risks are also covered. Active untreated infection, pregnancy, and suspected gynecologic malignancy are considered absolute contraindications to UAE, whereas contrast allergy, coagulopathy, desire for future fertility, and renal impairment are relative contraindications. Additional risks discussed with the patient include onset of menopause, arterial injury at the puncture site, clot formation, and in the case of concomitant fibroids, missed malignant tumor (leiomyosarcoma), and fibroid passage.

Results of laboratory testing, including complete blood count for platelet count, basic metabolic panel for potassium and creatinine, and international normalized ratio, are reviewed or tests are ordered if not available. Patients are then evaluated for their ability to undergo the procedure using moderate sedation.

Procedure

A pregnancy test is performed on the day of the procedure for all women of childbearing age. Patients refrain from eating and drinking 6 hours prior to UAE, and the procedure is performed under moderate sedation with fentanyl and midazolam. A Foley catheter is inserted into the urinary bladder prior to the start of the procedure.

Depending on the preference of the interventionalist, unilateral common femoral artery, bilateral common femoral artery (Figure 2), or left transradial access is obtained. The patient is provided prophylactic treatment with ketorolac and an antiemetic. The internal iliac artery is catheterized with a 4- to 5-F catheter. Either a 4- to 5-F catheter or a high-flow microcatheter is used to catheterize and embolize the uterine arteries. Attention is given to begin embolization distal to the origin of the cervicovaginal branches of the uterine artery, if visualized.

The embolic agent we use for embolization is Embosphere microspheres (Merit Medical Systems, Inc.) measuring 300–500 µm in diameter, although other
embolics such as particulate polyvinyl alcohol and Embozene microspheres (Boston Scientific Corporation) can also be used. Once two vials of Embosphere microspheres have been administered, the size of the microspheres may be upsized in diameter at the discretion of the operator. The recommended endpoint for embolization is near-stasis, as defined by the visualization of contrast within the transverse segment of the uterine artery for duration of time equivalent to five heartbeats. Preservative-free lidocaine (50 mg) is then administered into the uterine artery. A recent prospective randomized study showed improvement in postprocedural pain at 4 hours with the use of intra-arterial lidocaine.

Aortography may be performed in patients who have previously undergone pelvic surgery, those with a suspected ovarian artery or other collateral (Figure 3), or those with an outside MRI that was performed without the MRA component. At the completion of the procedure, all catheters are removed and hemostasis is achieved with manual compression or with use of an arterial closure device at the discretion of the operator.

Postprocedural Management
Embolication of adenomyosis is often associated with greater pain than typically experienced by patients who undergo embolization for fibroids alone, and it is important to have a pain management protocol in place. Patients are immediately provided with a patient-controlled analgesia pump following the procedure. Intravenous ketorolac is given at scheduled intervals to address postembolization inflammation, and patients are admitted for 23-hour observation. More recently, there are proponents for scheduling same-day discharge, particularly for those who undergo the procedure using a radial artery approach or arterial closure device. It is the opinion of the authors that significant pain and nausea control is commonly needed for the first night after UAE for adenomyosis, and this is done most safely within the hospital setting. Further investigation is needed to evaluate newer pain control methods in conjunction with maintaining successful UAE outcomes.

The morning after the procedure, the patient-controlled analgesia is discontinued and a trial of oral analgesics is presented before the patient is discharged home on scheduled ibuprofen with an oral narcotic for breakthrough pain, if needed. Patients then receive a phone call approximately 48 hours after discharge, and a 3-month clinical follow-up is scheduled. MRI at 3 months is reviewed during the clinic visit for degree of infarction, decrease in uterine size, and any complicating factors (Figure 4).

Outcomes
Previous case studies have shown favorable short-term outcomes for symptom relief after UAE for adenomyosis; however, recurrence rates are higher than for the treatment of fibroids. Popovic et al revealed 83.8% of pure adenomyosis patients experienced symptom relief with a median follow-up of 9.4 months, but only 64.9% of patients experienced sustained improvement after a median follow-up of 40.6 months. Overall uterine volumes decreased by 23% to 32% (including those with combined adenomyosis and fibroids). Complications included amenorrhea (20.9%) and eventual hysterectomy (12.8%). Of note, all amenorrheic patients were older than 45 years.

A recent review and meta-analysis showed overall symptom improvement in 83.1% of patients who underwent UAE for adenomyosis.
Figure 4. Postembolization T2-weighted MRI showing decreased overall size of the uterus and decreased prominence of the diffuse adenomyosis seen in Figure 1.

ment was separated into four groups: short-term pure adenomyosis (89.6%), short-term adenomyosis with fibroids (94.3%), long-term pure adenomyosis (74.0%), and long-term combined adenomyosis (84.5%), and good initial outcomes were found but with less of a sustained response. Percentage of uterine volume reduction was greater and statistically significant in the pure adenomyosis group at 3 months, but results were similar between the groups at 6- and 12-month follow-up. Amenorrhea was reported in 6.3% of all patients, and all of these patients were older than 40 years. The need for hysterectomy varied between groups in the short term, with 2.6% of pure adenomyosis patients and only 1.4% of combined adenomyosis patients undergoing hysterectomy; however, there was no significant difference in these patient groups in the long term (7.2% vs 7%).

CONCLUSION

Patients with adenomyosis often experience abnormal uterine bleeding and dysmenorrhea. A range of treatment options is available depending on the patient’s age and comorbidities, type of adenomyosis, desire for future fertility, and desire to maintain their uterus. UAE offers favorable short-term outcomes for patients with adenomyosis, but further randomized controlled trials are needed to determine if symptom resolution is sustainable and explore the impact on fertility. Although recurrence rates are higher than for fibroids, UAE for adenomyosis offers symptom relief in two-thirds of patients and is uterine sparing.


Theresa M. Caridi, MD
Assistant Professor
Division of Vascular and Interventional Radiology
MedStar Georgetown University Hospital
Washington, DC
theresa.m.caridi@gunet.georgetown.edu
Disclosures: Consultant to Vascular Solutions.

James B. Spies, MD, MPH
Professor and Chairman
Department of Radiology
Division of Vascular and Interventional Radiology
MedStar Georgetown University Hospital
Washington, DC
spiesj@gunet.georgetown.edu
Disclosures: None.